SurModics, Inc.

New MatrixGuard Diluents Reduce the Risk of False Positives
Chemicals & Gases

New MatrixGuard Diluents Reduce the Risk of False Positives

The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...

Read More »
Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous...

Read More »
Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter

The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation...

Read More »
Chemicals & Gases

SurModics Expands Protein-Free Stabilizer Line with AP Option

AACC Annual Meeting and Clinical Lab Expo 2014 EDEN PRAIRIE, Minn.-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is introducing StabilZyme® Protein-Free AP Stabilizer at the American Association for Clinical Chemistry meeting currently taking place in Chicago. “Protein interference is a...

Read More »

TMB Stop Solution is non-corrosive and non-hazardous.

BioFX® Liquid Nova-Stop Solution provides non-corrosive, non-hazardous stop solution for TMB microwell substrates. While offering alternative to stop solutions that contain sulfuric acid or hydrochloric acid, product also exhibits minimal signal drift. ELISA assay kit manufacturers can include solution in their products without needing to label and ship products as corrosive, and no...

Read More »
Chemicals & Gases

SurModics IVD Breakthrough Stabilizer Addresses Industry Challenge

EDEN PRAIRIE, Minn.Â- – SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is launching its new StabilZyme® Protein-Free Stabilizer today at the American Association for Clinical Chemistry (AACC) meeting in Houston. “This newest addition to SurModics’ stabilization line is significant for...

Read More »
Paints & Coatings

SurModics' New Low Friction, Low Particulate Device Coatings Introduced

SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings EDEN PRAIRIE, Minn.--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™ lubricious coatings for endovascular medical devices. Serene coatings are a breakthrough technology that delivers lubricity and...

Read More »
Laboratory and Research Supplies and Equipment

Immunodiagnostic Reagent offers 2-year stability.

Maintaining stability for 2 years at 25°C or 4 years at 4°C, BioFX® TMB Enhanced HRP Membrane Substrate is suited for diagnostic kits and point-of-care applications. One-component formulation is ready to use with no mixing. Product minimizes membrane wash out at high peroxidase concentrations, allowing for measurement of extended dynamic range. Sensitivity is similar to most...

Read More »
Machinery & Machining Tools

SurModics and OakRiver Technology Collaborate on Advanced Coating Equipment

EDEN PRAIRIE, Minn.--Oct. 31, 2007--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today an agreement with OakRiver Technology, Inc. to collaborate on the development, manufacture, distribution and ongoing support of advanced coating equipment for the medical device industry. Under the terms of the...

Read More »
New MatrixGuard Diluents Reduce the Risk of False Positives
Chemicals & Gases

New MatrixGuard Diluents Reduce the Risk of False Positives

The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...

Read More »
People in the News

Surmodics Announces Leadership Change and Appointment of Interim CFO

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as...

Read More »
Mergers & Acquisitions

Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics’ design, development, hydrophilic coating technology and manufacturing capabilities will advance innovative platform technology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative...

Read More »
Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous...

Read More »
Company News

Surmodics to Host Virtual Annual Meeting of Shareholders

Virtual Meeting on February 21 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight, chair of the...

Read More »
Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter

The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation...

Read More »
Mergers & Acquisitions

SurModics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter Technologies

• Furthers transformation strategy with vascular expertise and RD capabilities • Brings unique catheter-based technology and development capabilities • Raising revenue guidance to adjusted range of $62 million to $66 million • GAAP EPS in range of $0.30 to $0.35 per share; non-GAAP EPS unchanged at $0.66 to $0.75 per share EDEN PRAIRIE, Minn.Â- – SurModics, Inc. (Nasdaq:SRDX), a...

Read More »
Mergers & Acquisitions

SurModics Acquires Creagh Medical, a Developer and Manufacturer of Balloon Catheters

Accelerates strategic transformation into a whole-product solutions provider Significantly advances company’s drug-coated balloon development and manufacturing capabilities Expands pipeline of product development opportunities EDEN PRAIRIE, Minn. - SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has acquired Creagh...

Read More »
Chemicals & Gases

SurModics Expands Protein-Free Stabilizer Line with AP Option

AACC Annual Meeting and Clinical Lab Expo 2014 EDEN PRAIRIE, Minn.-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is introducing StabilZyme® Protein-Free AP Stabilizer at the American Association for Clinical Chemistry meeting currently taking place in Chicago. “Protein interference is a...

Read More »

TMB Stop Solution is non-corrosive and non-hazardous.

BioFX® Liquid Nova-Stop Solution provides non-corrosive, non-hazardous stop solution for TMB microwell substrates. While offering alternative to stop solutions that contain sulfuric acid or hydrochloric acid, product also exhibits minimal signal drift. ELISA assay kit manufacturers can include solution in their products without needing to label and ship products as corrosive, and no...

Read More »

All Topics